SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Pediatrix Medical Group, Inc. (MD) trades at a trailing P/E of 10.9, forward P/E of 10.1. Trailing earnings yield is 9.20%, forward earnings yield 9.88%. PEG 0.67 (Peter Lynch undervalued ≤1.0). Graham Number is $21.26.
Criteria proven by this page:
- VALUE (43/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 10.1 (down from trailing 10.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.67 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 9.20% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 9.88% as earnings recover.
- Analyst consensus target $20.67 (-8.6% downside) — slight downside risk — the market may be ahead of analyst expectations.
Overall SharesGrow Score: 44/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
43/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MD
Valuation Multiples
P/E (TTM)10.9
Forward P/E10.1
PEG Ratio0.67
Forward PEG0.67
P/B Ratio2.08
P/S Ratio0.92
EV/EBITDA7.7
Per Share Data
EPS (TTM)$1.96
Forward EPS (Est.)$2.24
Book Value / Share$10.26
Revenue / Share$22.67
FCF / Share$2.99
Yields & Fair Value
Earnings Yield9.20%
Forward Earnings Yield9.88%
Dividend Yield0.00%
Graham Number$21.26
SharesGrow IV$46.10 (+103.9%)
Analyst Target$20.67 (-8.6%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
19.0 |
-5.67 |
2.23 |
1.94 |
- |
| 2017 |
15.4 |
-10.70 |
1.61 |
1.43 |
- |
| 2018 |
11.2 |
-0.81 |
0.97 |
0.82 |
- |
| 2019 |
-1.6 |
0.00 |
1.56 |
1.32 |
- |
| 2020 |
-2.6 |
0.06 |
2.81 |
1.21 |
- |
| 2021 |
18.0 |
-0.15 |
2.62 |
1.23 |
- |
| 2022 |
18.6 |
-0.39 |
1.38 |
0.63 |
- |
| 2023 |
-12.9 |
0.07 |
0.92 |
0.39 |
- |
| 2024 |
-11.0 |
-0.17 |
1.43 |
0.54 |
- |
| 2025 |
11.0 |
-0.04 |
2.11 |
0.95 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$3.47 |
$3.18B |
$324.91M |
10.2% |
| 2017 |
$3.42 |
$3.46B |
$320.37M |
9.3% |
| 2018 |
$2.93 |
$3.65B |
$268.63M |
7.4% |
| 2019 |
$-13.77 |
$3.51B |
$-1.15B |
-32.7% |
| 2020 |
$-0.11 |
$1.73B |
$-9.58M |
-0.6% |
| 2021 |
$1.53 |
$1.91B |
$130.96M |
6.9% |
| 2022 |
$0.79 |
$1.97B |
$66.34M |
3.4% |
| 2023 |
$-0.73 |
$1.99B |
$-60.41M |
-3% |
| 2024 |
$-1.19 |
$2.01B |
$-99.07M |
-4.9% |
| 2025 |
$1.94 |
$1.91B |
$165.39M |
8.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$2.24 |
$2.21 – $2.26 |
$1.93B |
$1.91B – $1.95B |
5 |
| 2027 |
$2.33 |
$2.21 – $2.44 |
$1.98B |
$1.95B – $2B |
5 |
| 2028 |
$2.27 |
$2.07 – $2.41 |
$2.07B |
$2.07B – $2.07B |
3 |
| 2029 |
$2.05 |
$2.01 – $2.09 |
$2.22B |
$2.19B – $2.25B |
1 |
